Gilteritinib (Xospata)

From - A Hematology Oncology Wiki
Jump to navigation Jump to search

Mechanism of action

Tyrosine kinase inhibitor of FLT3, AXL, and ALK

Diseases for which it is used

History of changes in FDA indication

  • 2018-11-28: Initial FDA approval for treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation as detected by an FDA-approved test. (Based on ADMIRAL)

History of changes in EMA indication

  • 2019-10-24: Initial authorization

History of changes in Health Canada indication

  • 2019-12-23: Initial notice of compliance

History of changes in PMDA indication

  • 2018-09-21: New approval for the treatment of relapsed or refractory FLT3 mutation-positive acute myeloid leukemia.

Patient Drug Information

Also known as

  • Code name: ASP-2215
  • Brand name: Xospata